X0306 4 2022-01-01 false 0001590877 REGENXBIO Inc. RGNX 0001701180 Danos Olivier C/O REGENXBIO INC. 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850 false true false false Chief Scientific Officer Common Stock 2021-06-30 4 A false 555.00 33.0225 A 19598.00 D Common Stock 2021-12-31 4 A false 1.00 27.795 A 19599.00 D Common Stock 2022-01-01 4 F false 1221.00 32.70 D 18378.00 D Common Stock 2022-01-03 4 A false 10700.00 0.00 A 29078.00 D Stock Option (Right to Buy) 34.31 2022-01-03 4 A false 51100.00 0.00 A 2032-01-03 Common Stock 51100.00 51100.00 D The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the REGENXBIO Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of January 1, 2021 through June 30, 2021. This transaction is exempt under Rule 16b-3(c). In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 30, 2021. The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the ESPP for the ESPP purchase period of July 1, 2021 through December 31, 2021. This transaction is exempt under Rule 16b-3(c). In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on December 31, 2021. Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026 while the recipient provides continuous service to the Issuer. 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 3, 2023 while the optionee provides continuous service to the Issuer. /s/ Patrick J. Christmas as attorney-in-fact 2022-01-04